Sung-Whan Kim1, Mackenzie Houge2, Milton Brown3, Michael E Davis3, Young-Sup Yoon4. 1. Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; Institute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Incheon, South Korea; International St. Mary's Hospital, Incheon, South Korea; Department of Anatomy and Cell Biology and Mitochondria Hub Regulation Center, College of Medicine, Dong-A University, Busan, South Korea; Department of Cardiology, The Fourth Hospital of Harbin Medical University, Harbin, China. 2. Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia. 3. Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia. 4. Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia. Electronic address: yyoon5@emory.edu.
Abstract
BACKGROUND: Cell therapy for cardiovascular disease has been limited by low engraftment of administered cells and modest therapeutic effects. Bone marrow (BM) -derived CD31(+) cells are a promising cell source owing to their high angiovasculogenic and paracrine activities. OBJECTIVES: This study sought to identify culture conditions that could augment the cell adhesion, angiogenic, and anti-inflammatory activities of BM-derived CD31(+) cells, and to determine whether these cultured CD31(+) cells are effective for cardiac and vascular repair. METHODS: CD31(+) cells were isolated from human BM by magnetic-activated cell sorting and cultured for 10 days under hematopoietic stem cell, mesenchymal stem cell, or endothelial cell culture conditions. These cells were characterized by adhesion, angiogenesis, and inflammatory assays. The best of the cultured cells were implanted into myocardial infarction (MI) and hindlimb ischemia (HLI) models to determine therapeutic effects and underlying mechanisms. RESULTS: The CD31(+) cells cultured in endothelial cell medium (EC-CD31(+) cells) showed the highest adhesion and angiogenic activities and lowest inflammatory properties in vitro compared with uncultured or other cultured CD31(+) cells. When implanted into mouse MI or HLI models, EC-CD31(+) cells improved cardiac function and repaired limb ischemia to a greater extent than uncultured CD31(+) cells. Histologically, injected EC-CD31(+) cells exhibited higher retention, neovascularization, and cardiomyocyte proliferation. Importantly, cell retention and endothelial transdifferentiation was sustained up to 1 year. CONCLUSIONS: Short-term cultured EC-CD31(+) cells have higher cell engraftment, vessel-formation, cardiomyocyte proliferation, and anti-inflammatory potential, are highly effective for both cardiac and peripheral vascular repair, and enhance survival of mice with heart failure. These cultured CD31(+) cells may be a promising source for treating ischemic cardiovascular diseases.
BACKGROUND: Cell therapy for cardiovascular disease has been limited by low engraftment of administered cells and modest therapeutic effects. Bone marrow (BM) -derived CD31(+) cells are a promising cell source owing to their high angiovasculogenic and paracrine activities. OBJECTIVES: This study sought to identify culture conditions that could augment the cell adhesion, angiogenic, and anti-inflammatory activities of BM-derived CD31(+) cells, and to determine whether these cultured CD31(+) cells are effective for cardiac and vascular repair. METHODS:CD31(+) cells were isolated from human BM by magnetic-activated cell sorting and cultured for 10 days under hematopoietic stem cell, mesenchymal stem cell, or endothelial cell culture conditions. These cells were characterized by adhesion, angiogenesis, and inflammatory assays. The best of the cultured cells were implanted into myocardial infarction (MI) and hindlimb ischemia (HLI) models to determine therapeutic effects and underlying mechanisms. RESULTS: The CD31(+) cells cultured in endothelial cell medium (EC-CD31(+) cells) showed the highest adhesion and angiogenic activities and lowest inflammatory properties in vitro compared with uncultured or other cultured CD31(+) cells. When implanted into mouse MI or HLI models, EC-CD31(+) cells improved cardiac function and repaired limb ischemia to a greater extent than uncultured CD31(+) cells. Histologically, injected EC-CD31(+) cells exhibited higher retention, neovascularization, and cardiomyocyte proliferation. Importantly, cell retention and endothelial transdifferentiation was sustained up to 1 year. CONCLUSIONS: Short-term cultured EC-CD31(+) cells have higher cell engraftment, vessel-formation, cardiomyocyte proliferation, and anti-inflammatory potential, are highly effective for both cardiac and peripheral vascular repair, and enhance survival of mice with heart failure. These cultured CD31(+) cells may be a promising source for treating ischemic cardiovascular diseases.
Authors: Konstantinos E Hatzistergos; Henry Quevedo; Behzad N Oskouei; Qinghua Hu; Gary S Feigenbaum; Irene S Margitich; Ramesh Mazhari; Andrew J Boyle; Juan P Zambrano; Jose E Rodriguez; Raul Dulce; Pradip M Pattany; David Valdes; Concepcion Revilla; Alan W Heldman; Ian McNiece; Joshua M Hare Journal: Circ Res Date: 2010-07-29 Impact factor: 17.367
Authors: Vinodh Jeevanantham; Matthew Butler; Andre Saad; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn Journal: Circulation Date: 2012-06-22 Impact factor: 29.690
Authors: Ryang Hwa Lee; Andrey A Pulin; Min Jeong Seo; Daniel J Kota; Joni Ylostalo; Benjamin L Larson; Laura Semprun-Prieto; Patrice Delafontaine; Darwin J Prockop Journal: Cell Stem Cell Date: 2009-07-02 Impact factor: 24.633
Authors: Joshua M Hare; Joel E Fishman; Gary Gerstenblith; Darcy L DiFede Velazquez; Juan P Zambrano; Viky Y Suncion; Melissa Tracy; Eduard Ghersin; Peter V Johnston; Jeffrey A Brinker; Elayne Breton; Janice Davis-Sproul; Ivonne H Schulman; John Byrnes; Adam M Mendizabal; Maureen H Lowery; Didier Rouy; Peter Altman; Cheryl Wong Po Foo; Phillip Ruiz; Alexandra Amador; Jose Da Silva; Ian K McNiece; Alan W Heldman; Richard George; Albert Lardo Journal: JAMA Date: 2012-12-12 Impact factor: 56.272
Authors: Piotr Musialek; Lukasz Tekieli; Magdalena Kostkiewicz; Marcin Majka; Wojciech Szot; Zbigniew Walter; Anna Zebzda; Piotr Pieniazek; Andrzej Kadzielski; R Pawel Banys; Maria Olszowska; Mieczyslaw Pasowicz; Krzysztof Zmudka; Wieslawa Tracz Journal: J Nucl Cardiol Date: 2010-12-14 Impact factor: 5.952
Authors: Lingjun Wang; Elizabeth M Meier; Shuo Tian; Ienglam Lei; Liu Liu; Shaoxiang Xian; Mai T Lam; Zhong Wang Journal: Stem Cell Res Ther Date: 2017-10-16 Impact factor: 6.832